Brightseed Debuts Bio Gut Core™, a Low-Dose, Digestive Health Ingredient Clinically Proven to Strengthen Gut Barrier and Reduce Bloating and Abdominal Pain in Just Three Weeks
Today, Brightseed announced Bio Gut Core, a ready-to-use bioactive ingredient that delivers clinically-proven gut health benefits in low-dose, versatile ingredient applications. The launch coincides with the release of new human clinical trial data supporting the efficacy of Bio Gut Core to strengthen gut barrier function and promote digestive wellness within the study duration, three weeks, and for some subjects within one week of supplementation.
Brightseed and Haleon Announce Strategic Collaboration to Harness AI for Small Molecule Discovery and Human Health Innovation
Haleon (LSE: HLN), a global leader in consumer health, and Brightseed, the pioneer in AI-driven discovery of bioactive compounds, announced a new collaboration to advance the discovery of plant-based, small molecules with the potential to improve human health. This partnership will leverage Brightseed’s proprietary AI platform, Forager®, as a solution to accelerate scientific insights into the natural world and support Haleon’s mission to deliver innovative, science-led health solutions.
Brightseed Receives $1.6 Million Grant to Improve Birth Outcomes by Supporting Undernourished Pregnant and Nursing Mothers
Bioactives company Brightseed today announces its second grant from the Bill & Melinda Gates Foundation. Brightseed will use the $1.6 million funding to focus its artificial intelligence (AI) technology, Forager®, on identifying and validating natural bioactive compounds that target environmental enteric dysfunction (EED) in undernourished pregnant and lactating women, ultimately impacting global birth and infant outcomes.
ADM and Brightseed Launch Global Partnership To Decode How The Gut Microbiome & Bioactives Impact Human Health
ADM, a global leader in nutrition that powers many of the world’s top food, beverage, and health and wellness brands, and Brightseed, the bioactives company and a World Economic Forum Global Innovator, today announced a global joint partnership to develop evidence-based functional synbiotic products that target microbiome optimization with an undisclosed investment. ADM is leveraging Brightseed’s artificial intelligence (A.I.) platform, Forager®, to decipher the molecular interactions between dietary plants and gut microbes, and their potential impact on human health.
Brightseed Proclaims 2023 the Year of the Bioactivist as Consumer Interest in Nature-Derived Solutions Surges
Brightseed, the bioactives company, released new research today showing there is a significant subset of consumers who are engaged in a new horizon of science-based, natural solutions for health: bioactives.
Brightseed Preclinical Data Shows Potential for Bioactive Compounds to Support Gut Barrier Function
Brightseed, the bioactives company, today announced preclinical data in the peer-reviewed Journal of Food Bioactives showing that two bioactive compounds found in hemp hulls, N-trans caffeoyltyramine (NCT) and N-trans feruloyltyramine (NFT), have potential to support gut barrier function.1
Brightseed Introduces Bio 01™, the First Dietary Fiber with Bioactives to Support Gut Strength
Brightseed, the bioactive discovery company, announced today the launch of Brightseed Bio 01™, a novel dietary hemp fiber to support gut health formulated for use in food and beverages. Sourced from upcycled hemp hulls and formulated to optimize bioactive content, Brightseed Bio 01™ is the only dietary fiber on the market that contains two bioactive compounds that have shown the ability to support gut barrier integrity in preclinical studies.
Kallyope and Brightseed Enter Collaboration to Identify and Validate Novel Plant-Based Bioactives
Kallyope, a leading biotechnology company focused on identifying and developing therapeutics targeting the gut-brain axis, and Brightseed, creators of Forager®, a pioneering artificial intelligence platform that illuminates the connections between nature and human health, have entered a strategic research collaboration to screen plant compounds to identify and validate active agents that can be further derived into potential therapeutics targeting weight loss management and glucose control.
